Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2

Bone. 2004 Jan;34(1):140-7. doi: 10.1016/j.bone.2003.09.009.

Abstract

We have previously shown that a subcutaneous injection of glucagon-like peptide-2 (GLP-2) at 9 a.m. in fasting postmenopausal women results in a dose-dependent decrease in the serum concentration of fragments derived from the degradation of the C-terminal telopeptide region of collagen type I (s-CTX), a marker of bone resorption. In contrast, GLP-2 was found to have a neutral effect on bone formation, as assessed by serum osteocalcin. Since increased s-CTX levels are normally observed at night, we conducted bedtime studies in healthy postmenopausal women. The objective was to study the effect of GLP-2 injection on bone turnover given at bedtime. A total of 81 postmenopausal women were included in two randomised placebo-controlled studies. In conclusion, we found a dose-related reduction of s-CTX after injection of GLP-2 (P < 0.05) and osteocalcin levels was increased as compared to placebo (P = 0.07) by the treatment, suggestive of a stimulative effect on bone formation. An area under the curve (AUC0-10 h) analysis for s-CTX after GLP-2 injection confirmed the dose-related decrease as compared to placebo (P < 0.05).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Bone Resorption*
  • Collagen Type I / pharmacology
  • Dose-Response Relationship, Drug
  • Female
  • Glucagon-Like Peptide 2
  • Glucagon-Like Peptides
  • Humans
  • Injections, Subcutaneous
  • Middle Aged
  • Osteocalcin / blood
  • Peptides / administration & dosage*
  • Peptides / blood
  • Peptides / pharmacology*
  • Postmenopause

Substances

  • Collagen Type I
  • Glucagon-Like Peptide 2
  • Peptides
  • Osteocalcin
  • Glucagon-Like Peptides